Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The PREFERMS study: evaluating real-world patient retention on oral fingolimod compared with injectable disease modifying therapies in relapsing-remitting multiple sclerosis
Multiple Sclerosis
(-)
176
Authors/Disclosures
Nadia Tenenbaum, MD (EMD Serono Research & Development Institute)
PRESENTER
Dr. Tenenbaum has received personal compensation for serving as an employee of EMS Serono. Dr. Tenenbaum has stock in EMS Serono.
Lesley Schofield No disclosure on file
S. A. Josephson, MD, FÂé¶¹´«Ã½Ó³»­ (UCSF) Dr. Josephson has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Josephson has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for McGraw Hill---Harrison's Principles of Internal Medicine. Dr. Josephson has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for various legal firms. The institution of Dr. Josephson has received research support from NINDS. Dr. Josephson has received publishing royalties from a publication relating to health care. Dr. Josephson has received publishing royalties from a publication relating to health care.
Xiangyi Meng, PhD (Novartis) Dr. Meng has nothing to disclose.
Ralph Z. Kern, MD (Cognito Therapeutics) Dr. Kern has received personal compensation for serving as an employee of Cognito Therapeutics. Dr. Kern has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharmatrophix. Dr. Kern has or had stock in Cognito Therapeutics.